Merck receives EU committee approval recommendation for bladder cancer drug combo

Merck has obtained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its combination therapy for bladder cancer. This recommendation is a crucial step towards potential approval in the European Union, allowing for the treatment to be made available to patients suffering from this condition. The combination therapy aims to enhance treatment outcomes for individuals diagnosed with bladder cancer. Further steps will follow as Merck seeks formal approval from the European Commission.

Read More